This study tests a new medicine called verekitug (UPB-101) for adults with severe asthma. Asthma is a condition where it's hard to breathe because the airways in the lungs are narrowed. This study will check if verekitug helps reduce asthma attacks and how safe it is compared to a placebo (a harmless pill that looks like the real medicine). Participants will get shots under the skin (subcutaneously) of either verekitug or placebo. The study will have about 436 participants and will last up to 60 weeks, with some follow-ups for 16 weeks after the last dose.
- Participants will visit the study center regularly over the 60-week period.
- Participants will be randomly assigned to different dose groups.
- Compensation for participation will be provided.
How understandable was the trial content above?
Hard to understand
Easy to understand